Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Pediatr Crit Care Med. 2013 May;14(4):374–383. doi: 10.1097/PCC.0b013e318274568c

Table 3.

Observed Mortality and Lymphopenia at time of Second Interim DSMB Analysis

Outcome Treatment A N=133 Treatment B N=140 p-value
All Cause 28-Day Mortality 8/133 (6.0%) 16/137 (11.7%) 0.102
Prolonged Lymphopenia 13/133 (9.8%) 5/140 (3.6%) 0.039
Moderate Lymphopenia 32/133 (24.1%) 21/140 (15.0%) 0.0585

Note: 3 patients assigned to Treatment B had unknown 28-day mortality status.